Imaging genetics: implications for research on variable antidepressant drug response
暂无分享,去创建一个
Christian Scharinger | Ulrich Rabl | U. Rabl | C. Scharinger | L. Pezawas | Markus Müller | Markus Müller | Lukas Pezawas
[1] Dan J Stein,et al. Brain-Derived Neurotrophic Factor: The Neurotrophin Hypothesis of Psychopathology , 2008, CNS Spectrums.
[2] J. Groves,et al. Is it time to reassess the BDNF hypothesis of depression? , 2007, Molecular Psychiatry.
[3] Jeffrey H Meyer,et al. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. , 2007, Journal of psychiatry & neuroscience : JPN.
[4] Kiyotaka Nemoto,et al. Dose-dependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity , 2008, Neuroscience Research.
[5] R Todd Ogden,et al. Higher 5-HT1A Receptor Binding Potential During a Major Depressive Episode Predicts Poor Treatment Response: Preliminary Data from a Naturalistic Study , 2006, Neuropsychopharmacology.
[6] Leanne M Williams,et al. Brain derived neurotrophic factor Val66Met polymorphism, the five factor model of personality and hippocampal volume: Implications for depressive illness , 2009, Human brain mapping.
[7] B. Gutiérrez,et al. Evidence for a combined genetic effect of the 5-HT1A receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram , 2005, Journal of psychopharmacology.
[8] John Suckling,et al. Brain Imaging Correlates of Depressive Symptom Severity and Predictors of Symptom Improvement After Antidepressant Treatment , 2007, Biological Psychiatry.
[9] Dan J Stein. Depression, Anhedonia, and Psychomotor Symptoms: The Role of Dopaminergic Neurocircuitry , 2008, CNS Spectrums.
[10] M. Barrot,et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] R Kohnen,et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression , 2005, The Pharmacogenomics Journal.
[12] Marcus R. Munafò,et al. Serotonin Transporter (5-HTTLPR) Genotype and Amygdala Activation: A Meta-Analysis , 2008, Biological Psychiatry.
[13] G. Glover,et al. A Genetic Variant BDNF Polymorphism Alters Extinction Learning in Both Mouse and Human , 2010, Science.
[14] Marc Laruelle,et al. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. , 2004, The American journal of psychiatry.
[15] R A Bryant,et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety , 2009, Molecular Psychiatry.
[16] A. Seeringer,et al. Pharmacogenetics-guided dose modifications of antidepressants. , 2008, Clinics in laboratory medicine.
[17] I. Kirsch,et al. Efficacy of antidepressants in adults , 2005, BMJ : British Medical Journal.
[18] John D E Gabrieli,et al. Amygdala reactivity to emotional faces predicts improvement in major depression , 2005, Neuroreport.
[19] James R. MacFall,et al. The COMT Val158Met polymorphism and temporal lobe morphometry in healthy adults , 2007, Psychiatry Research: Neuroimaging.
[20] Walter Heindel,et al. Emotion specific modulation of automatic amygdala responses by 5-HTTLPR genotype , 2010, NeuroImage.
[21] M. Barrot,et al. Selective Loss of Brain-Derived Neurotrophic Factor in the Dentate Gyrus Attenuates Antidepressant Efficacy , 2008, Biological Psychiatry.
[22] M. Danhof,et al. The missing link between clinical endpoints and drug targets in depression. , 2010, Trends in pharmacological sciences.
[23] Ahmad R. Hariri,et al. Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission , 2009, Molecular Psychiatry.
[24] H. Möller,et al. Depression-related variation in brain morphology over 3 years: effects of stress? , 2008, Archives of general psychiatry.
[25] M. Trivedi,et al. Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder , 2009, Biological Psychiatry.
[26] Yinghui Hu,et al. BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation , 2008, Journal of neurochemistry.
[27] E. Smeraldi,et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.
[28] S. Leucht,et al. Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. , 2006, Pharmacogenomics.
[29] Andreas Meyer-Lindenberg,et al. Neural connectivity as an intermediate phenotype: Brain networks under genetic control , 2009, Human brain mapping.
[30] M. Lowe,et al. Activity and Connectivity of Brain Mood Regulating Circuit in Depression: A Functional Magnetic Resonance Study , 2005, Biological Psychiatry.
[31] K. Itoh,et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[32] P Riederer,et al. Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.
[33] S. Houle,et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. , 2001, The American journal of psychiatry.
[34] Rebecca Elliott,et al. The Effect of Citalopram Pretreatment on Neuronal Responses to Neuropsychological Tasks in Normal Volunteers: An fMRI Study , 2005, Neuropsychopharmacology.
[35] N. Ozaki,et al. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine , 2007, Journal of psychopharmacology.
[36] H. Smeets,et al. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors , 2007, International clinical psychopharmacology.
[37] Leanne M Williams,et al. COMT Val108/158Met polymorphism effects on emotional brain function and negativity bias , 2010, NeuroImage.
[38] J. John Mann,et al. Effect of BDNF val66met polymorphism on age-related amygdala volume changes in healthy subjects , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[39] H. Manji,et al. New insights into BDNF function in depression and anxiety , 2007, Nature Neuroscience.
[40] P. Zwanzger,et al. Serotonin-2A-receptor and -transporter polymorphisms: Lack of association in patients with major depression , 2001, European Neuropsychopharmacology.
[41] M. Fava,et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment , 2003, Biological Psychiatry.
[42] Stephan Ripke,et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. , 2009, Archives of general psychiatry.
[43] A. Meyer-Lindenberg,et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression , 2005, Nature Neuroscience.
[44] Dennis S. Charney,et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects , 2005, Biological Psychiatry.
[45] R. Elliott,et al. Neuronal effects of acute citalopram detected by pharmacoMRI , 2005, Psychopharmacology.
[46] D Robinson,et al. Brain-derived neurotrophic factor Val66met polymorphism and volume of the hippocampal formation , 2005, Molecular Psychiatry.
[47] T. Kinoshita,et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism , 2005, International clinical psychopharmacology.
[48] M. Essig,et al. Hippocampal volume in first episode and recurrent depression , 2009, Psychiatry Research: Neuroimaging.
[49] Francis J McMahon,et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. , 2007, Archives of general psychiatry.
[50] Cristina Cusin,et al. Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[51] H. Möller,et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[52] E. Smeraldi,et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. , 2000, Journal of clinical psychopharmacology.
[53] Enrico Simonotto,et al. The effects of escitalopram on working memory and brain activity in healthy adults during performance of the n-back task , 2006, Psychopharmacology.
[54] Lourdes Fañanás,et al. 5-HTTLPR Polymorphism of the Serotonin Transporter Gene Predicts Non-Remission in Major Depression Patients Treated With Citalopram in a 12-Weeks Follow Up Study , 2003, Journal of clinical psychopharmacology.
[55] Se-Won Lim,et al. Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder , 2006, Brain Research.
[56] G. Kranz,et al. Reward and the serotonergic system , 2010, Neuroscience.
[57] S. Cichon,et al. Neural Mechanisms of a Genome-Wide Supported Psychosis Variant , 2009, Science.
[58] J. Duncan,et al. Effects of the Brain-Derived Neurotrophic Growth Factor Val66Met Variation on Hippocampus Morphology in Bipolar Disorder , 2009, Neuropsychopharmacology.
[59] A. Schatzberg,et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. , 2004, Archives of general psychiatry.
[60] Kunihiko Ito,et al. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment , 2002, European Neuropsychopharmacology.
[61] Christian Montag,et al. The BDNF Val66Met polymorphism affects amygdala activity in response to emotional stimuli: Evidence from a genetic imaging study , 2008, NeuroImage.
[62] Justin S. Feinstein,et al. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. , 2005, Archives of general psychiatry.
[63] E. Smeraldi,et al. The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting , 2009, Psychopharmacology.
[64] Jun Yu Li,et al. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome , 2002, Biological Psychiatry.
[65] P. Nelemans,et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review , 2004, Molecular Psychiatry.
[66] A. Caspi,et al. Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.
[67] F. Gianfagna,et al. Meta-Analysis of the Brain-Derived Neurotrophic Factor Gene (BDNF) Val66Met Polymorphism in Anxiety Disorders and Anxiety-Related Personality Traits , 2008, Neuropsychobiology.
[68] B. Kolachana,et al. Variation in dopamine genes influences responsivity of the human reward system , 2009, Proceedings of the National Academy of Sciences.
[69] Anastasia Konsta,et al. Cingulate Neurobiology and Disease, B.A. Vogt (Ed.). Oxford University Press Inc., New York (2009), ISBN: 978-0-19-856696-0 , 2012 .
[70] Byung-Joo Ham,et al. Monoamine oxidase A–uVNTR genotype affects limbic brain activity in response to affective facial stimuli , 2008, Neuroreport.
[71] C. Clary,et al. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder , 2004, Psychopharmacology.
[72] Ariel Graff-Guerrero,et al. Frontal and limbic metabolic differences in subjects selected according to genetic variation of the SLC6A4 gene polymorphism , 2005, NeuroImage.
[73] Lukas Scheef,et al. No association of the Val66Met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression , 2009, Psychiatric genetics.
[74] T. Kinoshita,et al. Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients , 2006, Neuropsychobiology.
[75] M. Egan,et al. Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.
[76] Petti T. Pang,et al. The yin and yang of neurotrophin action , 2005, Nature Reviews Neuroscience.
[77] M. Raichle,et al. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism , 2002, European Neuropsychopharmacology.
[78] W. Drevets,et al. Imaging phenotypes of major depressive disorder: genetic correlates , 2009, Neuroscience.
[79] Mark Lau,et al. Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. , 2004, Archives of general psychiatry.
[80] Joseph E LeDoux,et al. Acute Selective Serotonin Reuptake Inhibitors Increase Conditioned Fear Expression: Blockade With a 5-HT2C Receptor Antagonist , 2007, Biological Psychiatry.
[81] P. Bandettini,et al. What's New in Neuroimaging Methods? , 2009, Annals of the New York Academy of Sciences.
[82] Antonio Cerasa,et al. MAO A VNTR polymorphism and variation in human morphology: a VBM study , 2008, Neuroreport.
[83] A. Serretti,et al. Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[84] M E Phelps,et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. , 2001, Archives of general psychiatry.
[85] Bruce S. McEwen,et al. Neurobiological and Clinical Effects of the Antidepressant Tianeptine , 2008, CNS drugs.
[86] Ge Zhang,et al. From Human Genetics and Genomics to Pharmacogenetics and Pharmacogenomics: Past Lessons, Future Directions , 2008 .
[87] P. Cowen,et al. Diminished Neural Processing of Aversive and Rewarding Stimuli During Selective Serotonin Reuptake Inhibitor Treatment , 2010, Biological Psychiatry.
[88] M. Raichle,et al. Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.
[89] J. Mazziotta,et al. Supraphysiological doses of levothyroxine alter regional cerebral metabolism and improve mood in bipolar depression , 2005, Molecular Psychiatry.
[90] Thomas E. Nichols,et al. Impact of complex genetic variation in COMT on human brain function , 2006, Molecular Psychiatry.
[91] Antonio Cerasa,et al. Impact of catechol-O-methyltransferase Val108/158 Met genotype on hippocampal and prefrontal gray matter volume , 2008, Neuroreport.
[92] John A. Detre,et al. Genetic Variation in Serotonin Transporter Alters Resting Brain Function in Healthy Individuals , 2007, Biological Psychiatry.
[93] Terry L. Jernigan,et al. Seasonal Changes in Brain Serotonin Transporter Binding in Short Serotonin Transporter Linked Polymorphic Region-Allele Carriers but Not in Long-Allele Homozygotes , 2010, Biological Psychiatry.
[94] John Suckling,et al. A Longitudinal Functional Magnetic Resonance Imaging Study of Verbal Working Memory in Depression After Antidepressant Therapy , 2007, Biological Psychiatry.
[95] T. Tencomnao,et al. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[96] S. Tsai,et al. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder , 2006, The Pharmacogenomics Journal.
[97] Vincent A Magnotta,et al. Hippocampal volume and 2-year outcome in depression. , 2008, The British journal of psychiatry : the journal of mental science.
[98] K. Lesch,et al. Long story short: the serotonin transporter in emotion regulation and social cognition , 2007, Nature Neuroscience.
[99] Marc Laruelle,et al. Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain , 2010, NeuroImage.
[100] I. Gottesman,et al. The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.
[101] M. Egan,et al. The BDNF val66met Polymorphism Affects Activity-Dependent Secretion of BDNF and Human Memory and Hippocampal Function , 2003, Cell.
[102] Eliza Congdon,et al. Additive effects of serotonin transporter and tryptophan hydroxylase-2 gene variation on neural correlates of affective processing , 2008, Biological Psychology.
[103] N. Logothetis. What we can do and what we cannot do with fMRI , 2008, Nature.
[104] Michael F Egan,et al. A susceptibility gene for affective disorders and the response of the human amygdala. , 2005, Archives of general psychiatry.
[105] M C O'Donovan,et al. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons , 2006, Molecular Psychiatry.
[106] John Suckling,et al. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. , 2004, Archives of general psychiatry.
[107] D. Blackwood,et al. Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy , 2009, The Pharmacogenomics Journal.
[108] René Hen,et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult , 2002, Nature.
[109] Kazuhiko Yanai,et al. Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention , 2009, NeuroImage.
[110] C. Nemeroff,et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. , 2010, The American journal of psychiatry.
[111] S. Rauch,et al. Neurobiology of emotion perception I: the neural basis of normal emotion perception , 2003, Biological Psychiatry.
[112] Giuseppe Blasi,et al. Neural mechanisms of genetic risk for impulsivity and violence in humans. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[113] C. Gross,et al. Postnatal handling reverses social anxiety in serotonin receptor 1A knockout mice , 2010, Genes, brain, and behavior.
[114] Andreas Heinz,et al. Catechol-O-Methyltransferase val158met Genotype Affects Processing of Emotional Stimuli in the Amygdala and Prefrontal Cortex , 2005, The Journal of Neuroscience.
[115] Timothy Edward John Behrens,et al. Contrasting roles for cingulate and orbitofrontal cortex in decisions and social behaviour , 2007, Trends in Cognitive Sciences.
[116] G. Jenkins,et al. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder , 2010, Biological Psychiatry.
[117] C. Montag,et al. The BDNF Val66Met polymorphism impacts parahippocampal and amygdala volume in healthy humans: incremental support for a genetic risk factor for depression , 2009, Psychological Medicine.
[118] Abraham Z. Snyder,et al. A default mode of brain function: A brief history of an evolving idea , 2007, NeuroImage.
[119] Michael J. Anderle,et al. The neural substrates of affective processing in depressed patients treated with venlafaxine. , 2003, The American journal of psychiatry.
[120] Eric J. Nestler,et al. The molecular neurobiology of depression , 2008, Nature.
[121] John Suckling,et al. Neural responses to happy facial expressions in major depression following antidepressant treatment. , 2007, The American journal of psychiatry.
[122] Francesco Fera,et al. Genetically dependent modulation of serotonergic inactivation in the human prefrontal cortex , 2008, NeuroImage.
[123] P. Cowen,et al. Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. , 2004, The American journal of psychiatry.
[124] K. Lesch,et al. CRSN Symposium : Focus on Depression , Part I Symposium du CRSN : le point sur la dépression , première partie Gene – environment interaction and the genetics of depression , 2004 .
[125] Gerty J. L. M. Lensvelt-Mulders,et al. Brain volume abnormalities in major depressive disorder: A meta‐analysis of magnetic resonance imaging studies , 2009, Human brain mapping.
[126] M. Fukuda,et al. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions , 2007, Psychiatry Research: Neuroimaging.
[127] A. Heinz,et al. Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype , 2007, Journal of Neural Transmission.
[128] C. Siao,et al. Genetic Variant BDNF (Val66Met) Polymorphism Alters Anxiety-Related Behavior , 2006, Science.
[129] R. Duman,et al. A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.
[130] M. Rietschel,et al. Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter. , 2000, Pharmacopsychiatry.
[131] F. Holsboer. How can we realize the promise of personalized antidepressant medicines? , 2008, Nature Reviews Neuroscience.
[132] Yong He,et al. Functional and Structural Connectivity Between the Perigenual Anterior Cingulate and Amygdala in Bipolar Disorder , 2009, Biological Psychiatry.
[133] S. Kapur,et al. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? , 2008, Schizophrenia bulletin.
[134] Yoshiro Okubo,et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET , 2003, Synapse.
[135] P. Muglia,et al. Genome-wide association study of recurrent major depressive disorder in two European case–control cohorts , 2010, Molecular Psychiatry.
[136] Hans-Jürgen Möller,et al. Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects , 2003, Biological Psychiatry.
[137] M. Furey,et al. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression , 2008, Brain Structure and Function.
[138] E. Castrén,et al. Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects , 2003, The Journal of Neuroscience.
[139] Eric Stice,et al. Frontal-Limbic White Matter Pathway Associations with the Serotonin Transporter Gene Promoter Region (5-HTTLPR) Polymorphism , 2009, The Journal of Neuroscience.
[140] Randy L. Gollub,et al. The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults , 2009, NeuroImage.
[141] Nicholas D. Walsh,et al. Functional Coupling of the Amygdala in Depressed Patients Treated with Antidepressant Medication , 2008, Neuropsychopharmacology.
[142] J Kirchheiner,et al. CYP2D6 in the brain: genotype effects on resting brain perfusion , 2011, Molecular Psychiatry.
[143] Steven P. Hamilton,et al. Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response , 2005, Biological Psychiatry.
[144] Ahmad R. Hariri,et al. Genetic Variation in Maoa Modulates Ventromedial Prefrontal Circuitry Mediating Individual Differences in Human Personality , 2022 .
[145] A. Meyer-Lindenberg,et al. The Brain-derived Neurotrophic Factor Val66met Polymorphism and Variation in Human Cortical Morphology , 2022 .
[146] E. Nestler,et al. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.
[147] R. Elliott,et al. Assessing human 5-HT function in vivo with pharmacoMRI , 2008, Neuropharmacology.
[148] R. Kahn,et al. Effects of brain‐derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia , 2010, Hippocampus.
[149] N. Ozaki,et al. Influence of the tyrosine hydroxylase val81met polymorphism and catechol‐O‐methyltransferase val158met polymorphism on the antidepressant effect of milnacipran , 2008, Human psychopharmacology.
[150] K. Lesch,et al. Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.
[151] D. Bylund,et al. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. , 2008, Pharmacology & therapeutics.
[152] D. Kumaran,et al. A Genetically Mediated Bias in Decision Making Driven by Failure of Amygdala Control , 2009, The Journal of Neuroscience.
[153] Hidehiro Iida,et al. The association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and morphological abnormalities of the brain in chronic schizophrenia. , 2006, Brain : a journal of neurology.
[154] S. Menzel,et al. Genetic and Molecular Analyses of Complex Metabolic Disorders: Genetic Linkage , 2002, Annals of the New York Academy of Sciences.
[155] H. Flor,et al. Gene–gene effects on central processing of aversive stimuli , 2007, Molecular Psychiatry.
[156] Joseph E. LeDoux,et al. The selective serotonin reuptake inhibitor citalopram increases fear after acute treatment but reduces fear with chronic treatment: a comparison with tianeptine , 2004, Biological Psychiatry.
[157] I. Lucki,et al. 5-HT1A receptor function in major depressive disorder , 2009, Progress in Neurobiology.
[158] L. Fañanás,et al. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. , 2006, Journal of affective disorders.
[159] J. Knowles,et al. Investigation of serotonin-related genes in antidepressant response , 2004, Molecular Psychiatry.
[160] Remco J. Renken,et al. Neuroticism modulates amygdala—prefrontal connectivity in response to negative emotional facial expressions , 2010, NeuroImage.
[161] Marcello Cadioli,et al. Neural and genetic correlates of antidepressant response to sleep deprivation: a functional magnetic resonance imaging study of moral valence decision in bipolar depression. , 2007, Archives of general psychiatry.
[162] A. Meyer-Lindenberg,et al. Intermediate phenotypes and genetic mechanisms of psychiatric disorders , 2006, Nature Reviews Neuroscience.
[163] M. Daly,et al. Genetic Mapping in Human Disease , 2008, Science.
[164] N. Kinukawa,et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. , 2008, The international journal of neuropsychopharmacology.
[165] Paul J. Harrison,et al. Catechol-o-Methyltransferase, Cognition, and Psychosis: Val158Met and Beyond , 2006, Biological Psychiatry.
[166] R. Hashimoto,et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. , 2006, Psychiatric genetics.
[167] P. Cowen,et al. A single dose of citalopram increases fear recognition in healthy subjects , 2007, Journal of psychopharmacology.
[168] P. Joyce,et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. , 2003, The international journal of neuropsychopharmacology.
[169] M. Wong,et al. Research and treatment approaches to depression , 2001, Nature Reviews Neuroscience.
[170] R. Hen,et al. Early-Life Blockade of the 5-HT Transporter Alters Emotional Behavior in Adult Mice , 2004, Science.
[171] G. Goodwin,et al. Polymorphism in serotonin transporter gene associated with susceptibility to major depression , 1996, The Lancet.
[172] W. Millard,et al. Assessment of Human Serotonin 1A Receptor Polymorphisms and SSRI Responsiveness , 2012, Molecular Diagnosis & Therapy.
[173] P. Albert,et al. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. , 2004, The international journal of neuropsychopharmacology.
[174] Michele T. Diaz,et al. Effect of bupropion extended release on negative emotion processing in major depressive disorder: a pilot functional magnetic resonance imaging study. , 2007, The Journal of clinical psychiatry.
[175] K. Ressler,et al. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic , 2007, Nature Neuroscience.
[176] Daniel R. Weinberger,et al. Variation of Human Amygdala Response During Threatening Stimuli as a Function of 5′HTTLPR Genotype and Personality Style , 2005, Biological Psychiatry.
[177] V. Arango,et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. , 2000, Archives of general psychiatry.
[178] Lucy R Forrest,et al. Fluoxetine (Prozac) Binding to Serotonin Transporter Is Modulated by Chloride and Conformational Changes , 2009, The Journal of Neuroscience.
[179] Walter Heindel,et al. 5-HTTLPR Biases Amygdala Activity in Response to Masked Facial Expressions in Major Depression , 2008, Neuropsychopharmacology.
[180] A. Serretti,et al. The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. , 2004, The international journal of neuropsychopharmacology.
[181] D. Nutt,et al. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression , 2009, European Neuropsychopharmacology.
[182] V. Arolt,et al. Serotonin receptor 1A −1019C/G variant: Impact on antidepressant pharmacoresponse in melancholic depression? , 2008, Neuroscience Letters.
[183] Amit Anand,et al. Brain Imaging Studies in Mood and Anxiety Disorders , 2003, Annals of the New York Academy of Sciences.
[184] Tilo Kircher,et al. COMT genotype and its role on hippocampal–prefrontal regions in declarative memory , 2010, NeuroImage.
[185] P. Gaspar,et al. The developmental role of serotonin: news from mouse molecular genetics , 2003, Nature Reviews Neuroscience.
[186] M. Wong,et al. Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response. , 2009, Archives of general psychiatry.
[187] D. Schaid,et al. SLC6A4 variation and citalopram response , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[188] J. Geddes,et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis , 2009, The Lancet.
[189] Peter N. C. Mohr,et al. Genetic variation in dopaminergic neuromodulation influences the ability to rapidly and flexibly adapt decisions , 2009, Proceedings of the National Academy of Sciences.
[190] S. Ryu,et al. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment , 2004, Psychiatric genetics.
[191] P. Gaspar,et al. New perspectives on the neurodevelopmental effects of SSRIs. , 2010, Trends in pharmacological sciences.
[192] Helen S Mayberg,et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. , 2007, The American journal of psychiatry.
[193] Pienie Zwitserlood,et al. Reduced amygdala-prefrontal coupling in major depression: association with MAOA genotype and illness severity. , 2009, The international journal of neuropsychopharmacology.
[194] Eliza Congdon,et al. Neural correlates of epigenesis , 2006, Proceedings of the National Academy of Sciences.
[195] Glenda M. MacQueen,et al. Posterior Hippocampal Volumes Are Associated with Remission Rates in Patients with Major Depressive Disorder , 2008, Biological Psychiatry.
[196] D. Lawlor,et al. Genetic association study of BDNF in depression: Finding from two cohort studies and a meta‐analysis , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[197] M. Rietschel,et al. Moderation of antidepressant response by the serotonin transporter gene , 2009, British Journal of Psychiatry.
[198] J. McKenzie,et al. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. , 2007, The Cochrane database of systematic reviews.
[199] Yang Wang,et al. Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. , 2007, The Journal of neuropsychiatry and clinical neurosciences.
[200] Harald H. Sitte,et al. Imaging genetics of mood disorders , 2010, NeuroImage.
[201] S Cichon,et al. Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task , 2011, Molecular Psychiatry.
[202] H. Breiter,et al. BDNF, relative preference, and reward circuitry responses to emotional communication , 2009, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[203] Monique Ernst,et al. fMRI predictors of treatment outcome in pediatric anxiety disorders , 2007, Psychopharmacology.
[204] B. Lebowitz,et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.
[205] B. Franke,et al. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity , 2010, Molecular Psychiatry.
[206] B. Ravnkilde,et al. Hippocampal volume and depression: a meta-analysis of MRI studies. , 2004, The American journal of psychiatry.
[207] M. Skolnick,et al. Evidence for HTR1A and LHPP as interacting genetic risk factors in major depression , 2009, Molecular Psychiatry.
[208] Sylvain Houle,et al. Novel 5-HTTLPR Allele Associates with Higher Serotonin Transporter Binding in Putamen: A [11C] DASB Positron Emission Tomography Study , 2007, Biological Psychiatry.
[209] V. Arolt,et al. Human Fear Conditioning and Extinction in Neuroimaging: A Systematic Review , 2009, PloS one.
[210] B. V. Zwieten-Boot,et al. A regulatory Apologia — A review of placebo-controlled studies in regulatory submissions of new-generation antidepressants , 2008, European Neuropsychopharmacology.
[211] Christian Büchel,et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter , 2005, Nature Neuroscience.
[212] David Goldman,et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. , 2006, American journal of human genetics.
[213] S. Nanko,et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder , 1997, Molecular Psychiatry.
[214] A. Serretti,et al. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder , 2010, Molecular Psychiatry.
[215] A. Janssens,et al. Meta-analyses of genetic studies on major depressive disorder , 2008, Molecular Psychiatry.
[216] David Goldman,et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. , 2006, The American journal of psychiatry.
[217] M. McInnis,et al. Psychiatric genetics: progress amid controversy , 2008, Nature Reviews Genetics.
[218] Deborah A Yurgelun-Todd,et al. Hippocampal volume in primary unipolar major depression: a magnetic resonance imaging study , 2000, Biological Psychiatry.
[219] Joseph H. Callicott,et al. Impact of interacting functional variants in COMT on regional gray matter volume in human brain , 2009, NeuroImage.
[220] A. Meyer-Lindenberg,et al. Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression , 2008, Molecular Psychiatry.
[221] B. Carroll,et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. , 2006, JAMA.
[222] Russell A. Poldrack,et al. Guidelines for reporting an fMRI study , 2008, NeuroImage.
[223] P. Jerabek,et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response , 2000, Biological Psychiatry.
[224] Nikos K Logothetis,et al. The ins and outs of fMRI signals , 2007, Nature Neuroscience.
[225] Carol Dobson-Stone,et al. Disturbances in selective information processing associated with the BDNF Val66Met polymorphism: Evidence from cognition, the P300 and fronto-hippocampal systems , 2009, Biological Psychology.
[226] Dan J Stein,et al. Psychobiology of Mindfulness , 2008, CNS Spectrums.
[227] Gloria Olivieri,et al. ‘Negativity bias’ in risk for depression and anxiety: Brain–body fear circuitry correlates, 5-HTT-LPR and early life stress , 2009, NeuroImage.
[228] Andreas Meyer-Lindenberg,et al. Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. , 2006, Archives of general psychiatry.
[229] J. Price,et al. Glial reduction in the subgenual prefrontal cortex in mood disorders. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[230] J. Potash,et al. Novel loci for major depression identified by genome-wide association study of STAR*D and meta-analysis of three studies , 2009, Molecular Psychiatry.
[231] V. Arolt,et al. Association of the COMT val158met Variant with Antidepressant Treatment Response in Major Depression , 2008, Neuropsychopharmacology.
[232] A. Meyer-Lindenberg,et al. Neural substrates of pleiotropic action of genetic variation in COMT: a meta-analysis , 2010, Molecular Psychiatry.
[233] C. Cusin,et al. Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. , 2002, The international journal of neuropsychopharmacology.
[234] M. Wong,et al. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[235] A. Simmons,et al. Escitalopram effects on insula and amygdala BOLD activation during emotional processing , 2008, Psychopharmacology.
[236] J. Ashburner,et al. Prognostic and Diagnostic Potential of the Structural Neuroanatomy of Depression , 2009, PloS one.
[237] Margot Albus,et al. Serotonin transporter promoter and intron 2 polymorphisms: relationship between allelic variants and gene expression , 2004, Biological Psychiatry.
[238] M. Egan,et al. Brain-Derived Neurotrophic Factor val66met Polymorphism Affects Human Memory-Related Hippocampal Activity and Predicts Memory Performance , 2003, The Journal of Neuroscience.
[239] S. Rauch,et al. Neurobiology of emotion perception II: implications for major psychiatric disorders , 2003, Biological Psychiatry.
[240] D. A. Lewis,et al. SERT-ainly involved in depression, but when? , 2006, The American journal of psychiatry.
[241] J. Hirschhorn,et al. A comprehensive review of genetic association studies , 2002, Genetics in Medicine.
[242] K. Ressler,et al. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories , 2007, Molecular Psychiatry.
[243] S. Tsai,et al. Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders , 2006, European Neuropsychopharmacology.
[244] H. Möller,et al. Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression , 2008, Molecular Psychiatry.
[245] E. Castrén,et al. Is mood chemistry? , 2005, Nature Reviews Neuroscience.
[246] Gustavo Turecki,et al. Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide , 2003, The Journal of Neuroscience.
[247] K. Itoh,et al. Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder , 2002, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[248] Andrew J. Saykin,et al. Voxelwise genome-wide association study (vGWAS) , 2010, NeuroImage.
[249] B. Carroll,et al. Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.
[250] Morten L. Kringelbach,et al. The personality trait openness is related to cerebral 5-HTT levels , 2009, NeuroImage.
[251] M. Gratacós,et al. A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders , 2008, The Pharmacogenomics Journal.
[252] Clare E. Mackay,et al. A Systematic Review of Diffusion Tensor Imaging Studies in Affective Disorders , 2009, Biological Psychiatry.
[253] M. Goodell,et al. Genome-wide association study of recurrent early-onset major depressive disorder , 2010, Molecular Psychiatry.
[254] S. Tsai,et al. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders , 2002, Molecular Psychiatry.
[255] A. Kersting,et al. Serotonergic genes modulate amygdala activity in major depression , 2007, Genes, brain, and behavior.
[256] Blair T. Johnson,et al. Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.
[257] Patrick M Fisher,et al. Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity , 2008, Neuropsychopharmacology.
[258] D. Ye,et al. Meta-analysis of BDNF Val66Met polymorphism association with treatment response in patients with major depressive disorder , 2010, European Neuropsychopharmacology.
[259] John P Hatch,et al. Neuronal Correlates of Brain-derived Neurotrophic Factor Val66Met Polymorphism and Morphometric Abnormalities in Bipolar Disorder , 2009, Neuropsychopharmacology.
[260] E. Rolls,et al. The orbitofrontal cortex and beyond: From affect to decision-making , 2008, Progress in Neurobiology.
[261] Andreas Meyer-Lindenberg,et al. False positives in imaging genetics , 2008, NeuroImage.
[262] Yung-Tian A Gau,et al. Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients. , 2009, Journal of affective disorders.
[263] D. Hamer,et al. A functional polymorphism in the monoamine oxidase A gene promoter , 1998, Human Genetics.
[264] E. Pomarol-Clotet,et al. COMT Val158Met polymorphism in relation to activation and de-activation in the prefrontal cortex: A study in patients with schizophrenia and healthy subjects , 2010, NeuroImage.
[265] S. Tsai,et al. Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[266] Margit Burmeister,et al. BDNF Val66Met Allele Is Associated with Reduced Hippocampal Volume in Healthy Subjects , 2006, Biological Psychiatry.
[267] R Todd Constable,et al. Role of Variation in the Serotonin Transporter Protein Gene (SLC6A4) in Trait Disturbances in the Ventral Anterior Cingulate in Bipolar Disorder , 2009, Neuropsychopharmacology.
[268] Hans-Jürgen Möller,et al. Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. , 2008, Journal of psychiatry & neuroscience : JPN.
[269] A. Hariri,et al. Neuroimaging studies of serotonin gene polymorphisms: Exploring the interplay of genes, brain, and behavior , 2006, Cognitive, affective & behavioral neuroscience.
[270] B. McEwen,et al. Plasticity of the Hippocampus: Adaptation to Chronic Stress and Allostatic Load , 2001, Annals of the New York Academy of Sciences.
[271] P. Whalen,et al. The Structural Integrity of an Amygdala–Prefrontal Pathway Predicts Trait Anxiety , 2009, The Journal of Neuroscience.
[272] T. Werge,et al. Antidepressive-drug-induced bodyweight gain is associated with polymorphisms in genes coding for COMT and TPH1 , 2009, International clinical psychopharmacology.
[273] S. Kasper,et al. The role of pharmacogenetics in the treatment of depression and anxiety disorders , 2009, International clinical psychopharmacology.
[274] B. Ham,et al. Serotonergic genes and amygdala activity in response to negative affective facial stimuli in Korean women , 2008, Genes, brain, and behavior.
[275] Nick C. Fox,et al. Ten simple rules for reporting voxel-based morphometry studies , 2008, NeuroImage.
[276] C. Cusin,et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-httlpr in delusional and nondelusional depression , 2001, Biological Psychiatry.
[277] D. Blackwood,et al. A splice site polymorphism in the G-protein &bgr; subunit influences antidepressant efficacy in depression , 2007, Pharmacogenetics and genomics.
[278] Hans-Jürgen Möller,et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. , 2007, Archives of general psychiatry.
[279] Siegfried Kasper,et al. Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study , 2010, NeuroImage.
[280] D. Kupfer,et al. Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression , 2000, Neuropsychopharmacology.
[281] Patrick M Fisher,et al. Effects of HTR1A C(-1019)G on amygdala reactivity and trait anxiety. , 2009, Archives of general psychiatry.
[282] Guy M. Goodwin,et al. Antidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues , 2006, Biological Psychiatry.
[283] Martha J. Farah,et al. COMT genotype influences prefrontal response to emotional distraction , 2006, Cognitive, affective & behavioral neuroscience.
[284] S. Alborzian,et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine , 1999, Psychiatry Research: Neuroimaging.
[285] M. Munafo,et al. The endophenotype concept in psychiatric genetics , 2006, Psychological Medicine.
[286] N. Božina,et al. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.
[287] Christian Büchel,et al. 5-HTT genotype effect on prefrontal–amygdala coupling differs between major depression and controls , 2009, Psychopharmacology.
[288] P. Cowen,et al. Increased Positive versus Negative Affective Perception and Memory in Healthy Volunteers following Selective Serotonin and Norepinephrine Reuptake Inhibition , 2022 .
[289] S. Tsai,et al. Association Study of a Monoamine Oxidase A Gene Promoter Polymorphism with Major Depressive Disorder and Antidepressant Response , 2005, Neuropsychopharmacology.
[290] Karl J. Friston,et al. Voxel-Based Morphometry—The Methods , 2000, NeuroImage.
[291] A. Serretti,et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients , 2007, Molecular Psychiatry.
[292] P. McGuffin,et al. Linkage and associated studies of schizophrenia. , 2000, American journal of medical genetics.
[293] R Todd Constable,et al. Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[294] E. Lander,et al. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.
[295] J. Sasse,et al. A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment , 2007, The Pharmacogenomics Journal.
[296] M. Ergun,et al. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. , 2008, Genetic testing.
[297] F. McMahon. Pioneering First Steps and Cautious Conclusions , 2010, Biological Psychiatry.
[298] M. Mintun,et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study , 2001, Biological Psychiatry.
[299] F. McMahon,et al. Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response. , 2009, The international journal of neuropsychopharmacology.
[300] D. Roden,et al. The genetic basis of variability in drug responses , 2002, Nature Reviews Drug Discovery.
[301] O. Taboureau,et al. Location of the Antidepressant Binding Site in the Serotonin Transporter , 2009, Journal of Biological Chemistry.
[302] E. Binder,et al. Pharmacogenomics of antidepressant drugs. , 2009, Pharmacology & therapeutics.
[303] R. Weinshilboum. Inheritance and drug response. , 2003, The New England journal of medicine.
[304] P. Fox,et al. Cingulate function in depression: a potential predictor of treatment response , 1997, Neuroreport.
[305] Takashi Asada,et al. The Val66Met polymorphism of the brain-derived neurotrophic factor gene affects age-related brain morphology , 2006, Neuroscience Letters.
[306] J. Hauser,et al. [Association between polymorphisms of Val66Met in the BDNF gene and the response to escitalopram and nortriptyline treatment in the light of the neurodevelopmental hypothesis of depression]. , 2008, Psychiatria polska.
[307] Sophia Frangou,et al. The effects of gender and COMT Val158Met polymorphism on fearful facial affect recognition: a fMRI study. , 2009, The international journal of neuropsychopharmacology.
[308] T. Lehtimäki,et al. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression , 2007, Journal of Neural Transmission.